Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
 Disease Category: Prostate Cancer
Location: United States, CO

Trial Information

Phase II, double blind, efficacy and safety study of Enzalutamide vs. Bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy.

This study compares the effect of treatment with enzalutamide (formerly known as MDV3100) to the effect of treatment with bicalutamide in prostate cancer patients whose cancer has progressed while receiving hormone therapy.

Patient Inclusion Criteria:

Men who are currently receiving hormonal treatment and are still progressing

Patient Exclusion Criteria:

Current treatment with bicalutamide and history of seizures

Candice Fortuna-Smith
The Urology Center of Colorado
2777 Mile High Stadium Cir
Denver, CO 80211
Phone: 303-783-2773
Fax: 303-421-1318
Email: cfortuna@tucc.com

View Map

Research Center Information: The Urology Center of Colorado

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.